ENTRY       D11812                      Drug
NAME        Pabinafusp alfa (genetical recombination) (JAN);
            Pabinafusp alfa (INN);
            Izcargo (TN)
SEQUENCE    (Heavy chain)
            EVQLVQSGAE VKKPGESLKI SCKGSGYSFT NYWLGWVRQM PGKGLEWMGD IYPGGDYPTY
            SEKFKVQVTI SADKSISTAY LQWSSLKASD TAMYYCARSG NYDEVAYWGQ GTLVTVSSAS
            TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
            YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS
            VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
            YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT
            KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
            GNVFSCSVMH EALHNHYTQK SLSLSPGKGS SETQANSTTD ALNVLLIIVD DLRPSLGCYG
            DKLVRSPNID QLASHSLLFQ NAFAQQAVCA PSRVSFLTGR RPDTTRLYDF NSYWRVHAGN
            FSTIPQYFKE NGYVTMSVGK VFHPGISSNH TDDSPYSWSF PPYHPSSEKY ENTKTCRGPD
            GELHANLLCP VDVLDVPEGT LPDKQSTEQA IQLLEKMKTS ASPFFLAVGY HKPHIPFRYP
            KEFQKLYPLE NITLAPDPEV PDGLPPVAYN PWMDIRQRED VQALNISVPY GPIPVDFQRK
            IRQSYFASVS YLDTQVGRLL SALDDLQLAN STIIAFTSDH GWALGEHGEW AKYSNFDVAT
            HVPLIFYVPG RTASLPEAGE KLFPYLDPFD SASQLMEPGR QSMDLVELVS LFPTLAGLAG
            LQVPPRCPVP SFHVELCREG KNLLKHFRFR DLEEDPYLPG NPRELIAYSQ YPRPSDIPQW
            NSDKPSLKDI KIMGYSIRTI DYRYTVWVGF NPDEFLANFS DIHAGELYFV DSDPLQDHNM
            YNDSQGGDLF QLLMP
            (Light chain)
            DIVMTQTPLS LSVTPGQPAS ISCRSSQSLV HSNGNTYLHW YLQKPGQSPQ LLIYKVSNRF
            SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQSTHVP WTFGQGTKVE IKRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
            (Disulfide bridge: H22-H96, H145-H201, H221-L219, H227-H'227, H230-H'230, H262-H322, H368-H426, H596-H609, H847-H857, H'22-H'96, H'145-H'201, H'221-L'219, H'262-H'322, H'368-H'426, H'596-H'609, H'847-H'857, L23-L93, L139-L199, L'23-L'93, L'139-L'199)
  TYPE      Peptide
REMARK      Therapeutic category: 3959
            Product: D11812<JP>
EFFICACY    Inherited metabolic disorder therapeutic agent
COMMENT     Fusion protein, enzyme-antibody
TARGET      IDS* [HSA_VAR:3423v1] [HSA:3423] [KO:K01136]
            TFRC (CD71) [HSA:7037] [KO:K06503]
  PATHWAY   hsa00531(3423)  Glycosaminoglycan degradation
            hsa04066(7037)  HIF-1 signaling pathway
            hsa04144(7037)  Endocytosis
            hsa04145(7037)  Phagosome
            hsa04142(3423)  Lysosome
            hsa04216(7037)  Ferroptosis
            hsa04640(7037)  Hematopoietic cell lineage
BRITE       Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               395  Enzyme preparations
                3959  Others
                 D11812  Pabinafusp alfa (genetical recombination) (JAN); Pabinafusp alfa (INN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                TFRC (CD71)
                 D11812  Pabinafusp alfa (genetical recombination) (JAN) &lt;JP&gt;
             Enzymes
              Hydrolases (EC3)
               Sulfatases
                IDS* [HSA_VAR:3423v1]
                 D11812  Pabinafusp alfa (genetical recombination) (JAN) &lt;JP&gt;
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11812
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11812
DBLINKS     CAS: 2140211-48-7
            PubChem: 405226677
///
